| Autor: |
Filardi, Bruno Andraus, Monteiro, Valter Silva, Schwartzmann, Pedro Vellosa, do Prado Martins, Vivian, Zucca, Luis Eduardo Rosa, Baiocchi, Gabriela Crispim, Malik, Amyn A., Silva, Julio, Hahn, Anne M., Chen, Nicholas F. G., Pham, Kien, Pérez-Then, Eddy, Miric, Marija, Brache, Vivian, Cochon, Leila, Larocca, Rafael A., Mendez, Roberto Della Rosa, Bardini Silveira, Douglas, Pinto, Aguinaldo Roberto, Croda, Julio |
| Předmět: |
|
| Zdroj: |
Science Translational Medicine; 2/15/2023, Vol. 15 Issue 683, p1-9, 9p |
| Abstrakt: |
The emergence of the SARS-CoV-2 Omicron sublineages resulted in increased transmission rates and reduced protection from vaccines. To counteract these effects, multiple booster strategies were used in different countries, although data comparing their efficiency in improving protective immunity remain sparse, especially among vulnerable populations, including older adults. The inactivated CoronaVac vaccine was among the most widely distributed vaccine worldwide and was essential in the early control of SARS-CoV-2–related hospitalizations and deaths. However, it is not well understood whether homologous versus heterologous booster doses in those fully vaccinated with CoronaVac induce distinct humoral responses or whether these responses vary across age groups. We analyzed plasma antibody responses from CoronaVac-vaccinated younger or older individuals who received a homologous CoronaVac or heterologous BNT162b2 or ChAdOx1 booster vaccine. All three evaluated boosters resulted in increased virus-specific IgG titers 28 days after the booster dose. However, we found that both IgG titers against SARS-CoV-2 Spike or RBD and neutralization titers against Omicron sublineages were substantially reduced in participants who received homologous CoronaVac compared with the heterologous BNT162b2 or ChAdOx1 booster. This effect was specifically prominent in recipients >50 years of age. In this group, the CoronaVac booster induced low virus-specific IgG titers and failed to elevate neutralization titers against any Omicron sublineage. Our results point to the notable inefficiency of CoronaVac immunization and boosting in mounting protective antiviral humoral immunity, particularly among older adults, during the Omicron wave. These observations also point to benefits of heterologous regimens in high-risk populations fully vaccinated with CoronaVac. CoronaVac and Elderly Immunity: The inactivated CoronaVac vaccine has been one of the most globally distributed vaccines during the COVID-19 pandemic. However, the persistence of SARS-CoV-2 variants has resulted in the need for vaccine boosting. Filardi et al. characterized SARS-CoV-2–specific antibody responses in 293 non-hospitalized adults in Brazil and the Dominican Republic who had been initially vaccinated with two doses of CoronaVac followed by a homologous CoronaVac booster or heterologous vaccination with the mRNA vaccine BNT162b2 or the adenovirus vector–based vaccine ChAdOx1. All vaccine types increased virus specific IgG 28 days after boosting, but Spike and RBD-specific IgG titers as well as neutralizing antibody concentrations were markedly lower against Omicron subvariants in individuals >50 years old boosted with CoronaVac. These findings highlight the potential benefit of heterologous vaccine boosters for older individuals who were initially vaccinated with CoronaVac. —CF [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
